194 related articles for article (PubMed ID: 19249500)
21. Renalase, kidney function, and markers of endothelial dysfunction in renal transplant recipients.
Zbroch E; Małyszko J; Małyszko J; Koc-Żórawska E; Myśliwiec M
Pol Arch Med Wewn; 2012; 122(1-2):40-4. PubMed ID: 22237745
[TBL] [Abstract][Full Text] [Related]
22. Activation of endothelial and coagulation systems in left ventricular assist device recipients.
John R; Panch S; Hrabe J; Wei P; Solovey A; Joyce L; Hebbel R
Ann Thorac Surg; 2009 Oct; 88(4):1171-9. PubMed ID: 19766802
[TBL] [Abstract][Full Text] [Related]
23. Inflammation and endothelial activation are linked to renal function in long-term kidney transplantation.
Cottone S; Palermo A; Vaccaro F; Mulè G; Guarneri M; Arsena R; Vadalà A; Cerasola G
Transpl Int; 2007 Jan; 20(1):82-7. PubMed ID: 17181657
[TBL] [Abstract][Full Text] [Related]
24. Thrombin activatable fibrinolysis inhibitor (TAFI) and markers of endothelial cell injury in dialyzed patients with diabetic nephropathy.
Małyszko J; Małyszko JS; Hryszko T; Myśliwiec M
Thromb Haemost; 2004 Mar; 91(3):480-6. PubMed ID: 14983223
[TBL] [Abstract][Full Text] [Related]
25. Circulating visfatin in chronic obstructive pulmonary disease.
Liu X; Ji Y; Chen J; Li S; Luo F
Nutrition; 2009 Apr; 25(4):373-8. PubMed ID: 19056239
[TBL] [Abstract][Full Text] [Related]
26. Plasma concentration of visfatin is a new surrogate marker of systemic inflammation in type 2 diabetic patients.
Kang YS; Song HK; Lee MH; Ko GJ; Cha DR
Diabetes Res Clin Pract; 2010 Aug; 89(2):141-9. PubMed ID: 20409603
[TBL] [Abstract][Full Text] [Related]
27. Visfatin, low-grade inflammation and body mass index (BMI).
Samara A; Pfister M; Marie B; Visvikis-Siest S
Clin Endocrinol (Oxf); 2008 Oct; 69(4):568-74. PubMed ID: 18248642
[TBL] [Abstract][Full Text] [Related]
28. Serum visfatin as a non-traditional biomarker of endothelial dysfunction in chronic kidney disease: an Egyptian study.
Bessa SS; Hamdy SM; El-Sheikh RG
Eur J Intern Med; 2010 Dec; 21(6):530-5. PubMed ID: 21111939
[TBL] [Abstract][Full Text] [Related]
29. Coagulation and inflammation in overt diabetic nephropathy: association with hyperhomocysteinemia.
Aso Y; Yoshida N; Okumura K; Wakabayashi S; Matsutomo R; Takebayashi K; Inukai T
Clin Chim Acta; 2004 Oct; 348(1-2):139-45. PubMed ID: 15369747
[TBL] [Abstract][Full Text] [Related]
30. Serum levels of the adipokine visfatin are increased in pre-eclampsia.
Fasshauer M; Waldeyer T; Seeger J; Schrey S; Ebert T; Kratzsch J; Lossner U; Bluher M; Stumvoll M; Faber R; Stepan H
Clin Endocrinol (Oxf); 2008 Jul; 69(1):69-73. PubMed ID: 18034779
[TBL] [Abstract][Full Text] [Related]
31. Elevated visfatin/pre-B-cell colony-enhancing factor plasma concentration in ischemic stroke.
Lu LF; Yang SS; Wang CP; Hung WC; Yu TH; Chiu CA; Chung FM; Shin SJ; Lee YJ
J Stroke Cerebrovasc Dis; 2009; 18(5):354-9. PubMed ID: 19717018
[TBL] [Abstract][Full Text] [Related]
32. Upregulation of fibroblast growth factor-2 by visfatin that promotes endothelial angiogenesis.
Bae YH; Bae MK; Kim SR; Lee JH; Wee HJ; Bae SK
Biochem Biophys Res Commun; 2009 Feb; 379(2):206-11. PubMed ID: 19100714
[TBL] [Abstract][Full Text] [Related]
33. Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis.
Cerinic MM; Valentini G; Sorano GG; D'Angelo S; Cuomo G; Fenu L; Generini S; Cinotti S; Morfini M; Pignone A; Guiducci S; Del Rosso A; Kalfin R; Das D; Marongiu F
Semin Arthritis Rheum; 2003 Apr; 32(5):285-95. PubMed ID: 12701039
[TBL] [Abstract][Full Text] [Related]
34. Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans.
Liu SW; Qiao SB; Yuan JS; Liu DQ
Clin Endocrinol (Oxf); 2009 Aug; 71(2):202-7. PubMed ID: 19178507
[TBL] [Abstract][Full Text] [Related]
35. Is there a link between CD146, a novel adhesion molecule and other markers of endothelial dysfunction in nephrotic syndrome and continuous ambulatory peritoneal dialysis?
Małyszko J; Małyszko JS; Myśliwiec M
Thromb Res; 2005; 115(1-2):19-24. PubMed ID: 15567448
[TBL] [Abstract][Full Text] [Related]
36. Plasma visfatin level in lean women with PCOS: relation to proinflammatory markers and insulin resistance.
Gen R; Akbay E; Muslu N; Sezer K; Cayan F
Gynecol Endocrinol; 2009 Apr; 25(4):241-5. PubMed ID: 19408173
[TBL] [Abstract][Full Text] [Related]
37. Relationship of transforming growth factor-beta(1) with tumour necrosis factor-alpha and endothelial activation in patients with stable renal transplantation.
Palermo A; Mulè G; Vadalà A; Vaccaro F; Guarneri M; Arsena R; Briolotta C; Cerasola G; Cottone S
Nephrology (Carlton); 2008 Apr; 13(2):164-70. PubMed ID: 18275506
[TBL] [Abstract][Full Text] [Related]
38. Tumor necrosis factor-related apoptosis-inducing ligand is a marker of kidney function and inflammation in heart and kidney transplant recipients.
Malyszko J; Przybylowski P; Malyszko J; Koc-Zorawska E; Mysliwiec M
Transplant Proc; 2011 Jun; 43(5):1877-80. PubMed ID: 21693293
[TBL] [Abstract][Full Text] [Related]
39. Plasma visfatin concentrations after a lifestyle intervention were directly associated with inflammatory markers.
Bo S; Ciccone G; Baldi I; Gambino R; Mandrile C; Durazzo M; Gentile L; Cassader M; Cavallo-Perin P; Pagano G
Nutr Metab Cardiovasc Dis; 2009 Jul; 19(6):423-30. PubMed ID: 19073361
[TBL] [Abstract][Full Text] [Related]
40. The coagulo-lytic system and endothelial function in cyclosporine-treated kidney allograft recipients.
Malyszko J; Malyszko JS; Pawlak K; Mysliwiec M
Transplantation; 1996 Sep; 62(6):828-30. PubMed ID: 8824484
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
